ArticleMedicine2025
Impact of rheumatoid arthritis on Alzheimer's disease: A two-sample bidirectional Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunosuppressant Use Mediates Neuroprotection Against Alzheimer's Disease in Rheumatoid Arthritis-A Two-Step Mendelian Randomization and NHANES Study.International journal of rheumatic diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Controversial relationship of rheumatoid arthritis (RA) with Alzheimer disease (AD) risk has been reported in previous research. However, epidemiological studies are susceptible to confounding factors and reverse causality. This study aimed to explore the causal relationship between RA and AD by using a 2-sample bidirectional Mendelian randomization (MR) study. Genetic data for RA and AD were extracted from published genome-wide association study databases and the FinnGen project. The primary statistical method was inverse variance weighted, which was supplemented by MR Egger regression, weighted median, simple mode, and weighted mode methods. In addition, Cochran Q test, MR Egger intercept, and MR-PRESSO global test were used to detect heterogeneity and pleiotropy. Further sensitivity analyses were conducted using leave-one-out method and funnel plots, to evaluate the robustness of the results. Genetically predicted RA had a positive casual effect on the risk of AD development (inverse variance weighted odds ratio [OR] = 1.062, 95% confidence interval [CI] = 1.019-1.107, P = .004; weighted median OR = 1.073, 95% CI = 1.021-1.126, P = .005; weighted mode OR = 1.077, 95% CI = 1.025-1.131, P = .007). Notably, reverse MR analysis indicated no significant effect of AD on RA (all P > .05). No pleiotropy or heterogeneity was identified in the bidirectional MR analysis. And leave-one-out analysis and funnel plots confirmed the robustness and reliability of the findings. This study provides new evidence for the causal relationship between RA and the increased risk of AD. Early screening of cognitive function in patients with RA may be beneficial in preventing future AD progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.